An Open-Label Study of N-Acetyl Cysteine in Children With Autism
Trial ID or NCT#
NCT00676195
Status
NOT RECRUITING
Purpose
The purpose of the study is to test the tolerability and efficacy of N-Acetyl Cysteine (NAC) in children with Autism.
Official Title
An Open-Label Study of N-Acetyl Cysteine in Autism
Eligibility Criteria
Ages Eligible for Study: 3 Years to 12 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- Subjects will be eligible for this study if they participated in the Double-blind, randomized, placebo controlled study of N-Acetyl Cysteine in Autism study at Stanford University and meet all of the following criteria:
- 1. Outpatients between 3.0 and 12.11 years of age inclusive2. Males and females who are physically healthy3. diagnosis of autism based on Diagnostic and Statistical Manual (DSM-IV-TR) criteria, the Autism Diagnostic Interview-Revised, and expert clinical evaluation4. Clinical Global Impression Severity rating of 45. Care provider who can reliably bring subject to clinic visits, can provide trustworthy ratings, and interacts with subject on a regular basis6. Ability of subject to swallow the compound7. Stable concomitant medications for at least 2 weeks8. No planned changes in psychosocial interventions during the open-label N-Acetyl Cysteine trial
Exclusion Criteria:
- 1. Diagnostic and Statistical Manual (DSM-IV-TR) diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder, not otherwise specified2. Active medical problems: unstable seizures, significant physical illness (e.g., serious liver or renal pathology)3. Pregnancy or sexually active females4. Subjects taking antioxidant agents and glutathione prodrugs will be excluded from the study except if they have been off these compounds for at least 4 weeks
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Robin Libove
6507361235
View on ClinicalTrials.gov
